CRSP U.S. FDA approved first therapy utilising CRISPR
The beginning of a new era in medicine: The U.S. FDA has today approved cell-based gene therapy Casgevy, marking the first FDA-approved therapy utilising the genome editing technology CRISPR (NASDAQ:CRSP) | https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease #FDA #CRISPR #shorts
WA1 High grade central zone
WA1 Resources (ASX: WA1) announces further exploration results from drilling at the 100% owned West Arunta Project in Western Australia with assays from the central zone demonstrating continuity of the shallow high-grade blanket of niobium mineralisation https://app.sharelinktechnologies.com/announcement/asx/bcf96f0d9b1a1079082bc988d84a27df #shorts
BUB Achieves record weekly U.S. revenue of ~$770k
Bubs Australia (ASX:BUB) provided an update on the strong growth and accelerating consumer demand in the U.S. as it achieved record weekly revenue in the U.S. during November 2023 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231211/pdf/05ydpq3q5nxgbg.pdf #BUB #UnitedStates #shorts
SIG to merge with Chemist Warehouse Group
Sigma Healthcare (ASX:SIG) is to merge with CW Group Holdings (the Chemist Warehouse Group), creating a leading healthcare wholesaler, distributor and retail pharmacy franchisor. It combines SIG’s extensive and state-of-the-art distribution infrastructure with CW Group’s leading retailing know-how | ASX announcement: https://investorcentre.sigmahealthcare.com.au/static-files/d2c377b3-f487-4488-b34d-43c02330e6b7 #SIG #mergers #shorts
4DX Acquires Imbio
4DMedical (ASX:4DX) announces it has signed a binding agreement for the acquisition of Imbio, a U.S.-based medical technology company that uses artificial intelligence to turn standard-of-care CT scans into personalised medicine https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02752243-3A632933 #4DX #acquisition #shorts
CYP Phase 2 Trial approved
Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has received regulatory and ethics approval to commence its Phase 2 clinical trial at clinical centres in Turkey | ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/e0fa6ac7f7a6ddf39eef8d4299365c12 #shorts
LYC closer to expanding operating capacity
Lynas Rare Earths (ASX:LYC, OTC:LYSDY) announced that the first feed of material from its Mt Weld Mine into the company’s new Kalgoorlie Rare Earths Processing Facility, following completion of kiln heating and other commissioning activities | ASX announcement: https://wcsecure.weblink.com.au/pdf/LYC/02751000.pdf #rareearths #shorts
FSF Increased forecasted Farmgate Milk Price
Fonterra Shareholders’ Fund (ASX:FSF) increased its forecast Farmgate Milk Price and earnings guidance for FY24 following an increase in Global Dairy Trade prices and demand pickup from China | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231207/pdf/05y94j0v55brtl.pdf #shorts
PPT Announces a potential split into three companies
Perpetual (ASX:PPT) announced it has progressed the evaluation of its strategic options to the point where it will be exploring splitting the company into Corporate Trust, Wealth Management, and Asset Management | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231206/pdf/05y7pnj7ybss42.pdf #shorts
EDV Outlines a number of growth initiatives
Endeavour Group (ASX:EDV) has outlined a number of growth initiatives across the group’s Dan Murphy and BWS retail chains, Pinnacle Drinks business and stable of ALH hotels that are expected to help the company deliver the next phase of its expansion strategy | Investor presentation: https://announcements.asx.com.au/asxpdf/20231206/pdf/05y7qk0kx0qb76.pdf #hospitality #shorts